Catalog No.
EHK13702
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Thr263
Predicted molecular weight
29.61 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q6ZMC9
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CD33L3, Siglec-15, Sialic acid-binding Ig-like lectin 15, SIGLEC15, CD33 antigen-like 3
Anti-Tumor Activities of Anti-Siglec-15 Chimeric Heavy-Chain Antibodies., PMID:40507880
IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma., PMID:40500109
Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo., PMID:40365291
Siglec-15 antibody-GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages., PMID:40216442
Siglec-15 is a putative receptor for porcine epidemic diarrhea virus infection., PMID:40172660
Siglec-targeted liposomes to identify sialoglycans present on fungal pathogens., PMID:40084878
Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer., PMID:39940924
Screening and preparation of nanobodies for SIGLEC-15 detection., PMID:39880295
Targeting Siglec-15 mediates mitochondrial retrograde regulation of cervical cancer development., PMID:39756115
Siglec15 in blood system diseases: from bench to bedside., PMID:39697338
Killing two birds with one stone: Siglec-15 targeting integrated bioactive glasses hydrogel for treatment of breast cancer bone metastasis., PMID:39687802
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer., PMID:39609852
Expression of SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and breast cancer progression., PMID:39541298
Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism., PMID:39524871
Siglec-15 expression in diffuse gliomas and its correlation with MRI morphologic features and apparent diffusion coefficient., PMID:39434541
Aptamer-based Immune Checkpoint Inhibition for Cancer Immunotherapy., PMID:39417693
Decoding the Immune Response and Its Biomarker B2M for High Altitude Pulmonary Edema in Rat: Implications for Diagnosis and Prognosis., PMID:39411751
Differential expression of ST6GALNAC1 and ST6GALNAC2 and their clinical relevance to colorectal cancer progression., PMID:39348343
Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer., PMID:39301699
Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting., PMID:39220827
DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma., PMID:39087856
Eupatilin suppresses osteoclastogenesis and periodontal bone loss by inhibiting the MAPKs/Siglec-15 pathway., PMID:39047450
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion., PMID:38988824
Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor., PMID:38849345
The expression characteristic and prognostic role of Siglec-15 in lung adenocarcinoma., PMID:38725348
Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer., PMID:38652971
Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma., PMID:38531803
Comprehensive analysis of peroxisome proliferator-activated receptors to predict the drug resistance, immune microenvironment, and prognosis in stomach adenocarcinomas., PMID:38529307
The chromatin remodeling factor Arid1a cooperates with Jun/Fos to promote osteoclastogenesis by epigenetically upregulating Siglec15 expression., PMID:38477755
Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer., PMID:38468240
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis., PMID:38252825
The identification of a PTEN-associated gene signature for the prediction of prognosis and planning of therapeutic strategy in endometrial cancer., PMID:38192993
Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma., PMID:38182638
Siglec-15 regulates cell proliferation, migration and invasion in bladder cancer., PMID:38169162
Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma., PMID:38072971
Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy., PMID:37955317
Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study., PMID:37932988
Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes., PMID:37869015
Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer., PMID:37843557
Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas., PMID:37674198
Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis., PMID:37607544
The expression of two immunosuppressive SIGLEC family molecules in papillary thyroid cancer and their effect on prognosis., PMID:37480496
Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia., PMID:37465593
Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas., PMID:37325664
Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b., PMID:37311743
Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma., PMID:37234161
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma., PMID:37222841
Siglec15 promotes the migration of thyroid carcinoma cells by enhancing the EGFR protein stability., PMID:37129515
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions., PMID:37103472
Histochemical assessment on osteoclasts in long bones of toll-like receptor 2 (TLR2) deficient mice., PMID:37088152
For research use only. Not for human or drug use.
